EUVIMEDEUVIMED entdecken
Crossref

Optimization of performance of Dutch newborn screening for cystic fibrosis

M J Bouva, J E Dankert-Roelse, Cpb van der Ploeg, R K Verschoof-Puite, D D Zomer-van Ommen, Jjp Gille, B S Jakobs, Mla Heijnen, K M de Winter-de Groot

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2023.09.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von M J Bouva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dutch newborn screening (NBS) for Cystic Fibrosis (CF) introduced in 2011 showed a sensitivity of 90% and a positive predictive value (PPV) of 63%. We describe a study including an optimization phase and evaluation of the modified protocol. METHODS: Dutch protocol consists of four steps: determination of immunoreactive trypsinogen (IRT) and pancreatitis-associated protein (PAP), DNA analysis by INNO-LiPA and extended gene analysis (EGA). For the optimization phase we used results of 556,952 newborns screened between April 2011 and June 2014 to calculate effects of 13 alternative protocols on sensitivity, specificity, PPV, ratios of CF to other diagnoses, and costs. One alternative protocol was selected based on calculated sensitivity, PPV and costs and was implemented on 1st July 2016. In this modified protocol DNA analysis is performed in samples with a combination of IRT ≥60 µg/l and PAP ≥3.0 µg/l, IRT ≥100 µg/l and PAP ≥1.2 µg/l or IRT ≥124 µg/l and PAP not relevant. Results of 599,137 newborns screened between 1st July 2016 and 31st December 2019 were similarly evaluated as in the optimization phase. RESULTS: The modified protocol showed a sensitivity of 95%, PPV of 76%, CF to CF transmembrane conductance regulator-related metabolic syndrome/CF screen positive, inconclusive diagnoses (CRMS/CFSPID) ratio 12/1, CF/CF carrier ratio 4/1. Costs per screened newborn were slightly higher. Eleven children, of whom five with classic CF, would not have been referred with the previous protocol. CONCLUSIONS: The modified protocol results in acceptable sensitivity (95%) and good PPV of 76% with minimal increase in costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisChildInfant, NewbornHumansNeonatal ScreeningCystic Fibrosis Transmembrane Conductance RegulatorPancreatitis-Associated ProteinsTrypsinogenDNA

Stichwörter der Autor:innen

BloodspotCystic fibrosisDBS, The NetherlandsDNAIRTNewborn screeningPAP

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorPancreatitis-Associated ProteinsTrypsinogenDNA

Autor:innen und Institutionen

  • Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Department of Pediatrics, School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Department of Child Health, Netherlands Organisation for Applied Scientific Research (TNO), Leiden, the Netherlands.
  • Department of Vaccine Supply and Prevention Programmes, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Dutch CF Foundation, Baarn, the Netherlands.
  • Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands.

Zitieren

APA

Bouva, M. J., Dankert-Roelse, J. E., van der Ploeg, C., Verschoof-Puite, R. K., Zomer-van Ommen, D. D., Gille, J., Jakobs, B. S., Heijnen, M., & de Winter-de Groot, K. M. (2024). Optimization of performance of Dutch newborn screening for cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.09.001

Vancouver

Bouva MJ, Dankert-Roelse JE, van der Ploeg C, Verschoof-Puite RK, Zomer-van Ommen DD, Gille J, et al. Optimization of performance of Dutch newborn screening for cystic fibrosis. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2023.09.001

BibTeX
@article{Bouva2024,
  author = {Bouva, M J and Dankert-Roelse, J E and van der Ploeg, Cpb and Verschoof-Puite, R K and Zomer-van Ommen, D D and Gille, Jjp and Jakobs, B S and Heijnen, Mla and de Winter-de Groot, K M},
  title = {Optimization of performance of Dutch newborn screening for cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2023.09.001}
}
Kostenlos starten →